Virpax Pharmaceuticals, Inc. (VRPX)
| Market Cap | 1.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.07M |
| Shares Out | 1.06M |
| EPS (ttm) | -70.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 147,162 |
| Open | 1.450 |
| Previous Close | 1.480 |
| Day's Range | 1.260 - 1.455 |
| 52-Week Range | 1.260 - 106.750 |
| Beta | 0.96 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | May 12, 2025 |
About VRPX
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug produ... [Read more]
Financial Performance
Financial StatementsNews
Virpax Pharmaceuticals Announces Reverse Stock Split
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic st...
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
BERWYN, Penn.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic...
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Virpax's NES100 to be Presented at The Society of Toxicology by NCATS
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate
On Friday, Virpax Pharmaceuticals, Inc. VRPX completed the full study following the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing C...
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering
NEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service investment banking and financial advisory firm, is proud to announce its role as sole placement ...
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...
Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing pharmaceutical products for pain management, announced that ...
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering
New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceutical...
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems...
This FactSet Research Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)-- #earnings--Virpax Reports 2024 Second Quarter Results and Recent Developments.
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at Sidoti Virtual Investor Conference August 14-15.
Virpax Regains Compliance with Nasdaq Minimum Bid Price
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Regains Compliance with Nasdaq Minimum Bid Price.
Crude Oil Gains Over 1%; Virpax Pharmaceuticals Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday.
Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?
Wednesday, Virpax Pharmaceuticals Inc VRPX released results for a Swine Model pilot study for Probudur, Virpax's long-acting liposomal bupivacaine formulation injected at a wound site to provide immed...
What's Going With Penny Stock Virpax Pharmaceuticals On Monday?
Shares of Virpax Pharmaceuticals Inc VRPX are trading higher on Monday on a strong session volume of 22.8 million, as per data from Benzinga Pro.
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding.
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at 2024 BIO International Convention.